Skip to main content

Topic

Drug Labeling

96 published works

  1. Health Industry Washington Watch

    Hundreds of Drugs and Biologics Face Labeling Changes under New FDA Plan

    By Jennifer Pike

    In a notice published in the Federal Register on May 7, 2014, the U.S. Food and Drug Administration (“FDA”) announced its intent to incentivize manufacturers to voluntarily update their prescription…

  2. Louisiana Law Blog

    Louisiana Fourth Circuit Offers Clarification on the Role of Pharmaceutical Labeling and Package Inserts in Medical Malpractice Litigation: Deviation from manufacturer dosage instructions is not ipso facto evidence of breach

    By Karen Fontana Young

    The effect of a physician’s decision to deviate from the pharmaceutical company’s dosage instructions contained in a drug’s FDA approved package insert has been a recurring issue in medical malpractice…

  3. Dangerous Drugs & Medical Devices

    Our Comment in Support of the FDA’s Proposed Rule: Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products (78 Fed. Reg. 67985)

    By Radoslaw Pawluk

    Janice L. WeinerCenter for Drug Evaluation and ResearchFood and Drug Administration10903 New Hampshire Ave.Bldg. 51, Room 6304Silver Spring, MD 20993-0002  Dear Ms. Weiner, We are grateful for the opportunity to…

  4. Focus on Regulation

    FDA Proposes Rule Affecting Liability for Generic Drug Manufacturers

    By Robert Church, Lauren Colton, Jason F. Conaty

    On Wednesday, November 13, 2013, the Food and Drug Administration (FDA) issued a proposed rule under which generic drug manufacturers would be able to independently update the safety information accompanying…

  5. DEA Chronicles

    Changes Ahead: New Rules for Painkillers

    By Megan Scanlon

    FDA Announces New Labeling and Postmarket Studies Requirements for Painkillers On September 10, 2013, the FDA announced its plan to issue new regulations for labeling extended-release and long-acting (ER/LA) opioid analgesics…

  6. Defense Litigation Insider

    Massachusetts Court Finds Plaintiffs’ Claims Against Generic Drug Manufacturers Are Barred By Preemption

    By Jonathan F. Tabasky

    Written by Jonathan F. Tabasky and Kate B. Puccio Massachusetts Superior Court Judge Bruce R. Henry recently dismissed a series of claims against several manufacturers of the generic drug Metoclopramide…

  7. Drug & Device Law

    Revisiting Publisher (Non)Liability

    By Bexis

    We were perusing the recent GAO report on electronic drug labeling in our spare time (we’re weird like that).  We found a number of interesting points − such as what…

  8. Mass Tort Defense

    Supreme Court Issues Important Preemption Ruling

    By Sean Wajert

    The Supreme Court last week reversed the First Circuit decision in Mutual Pharmaceutical Co. v. Bartlett, No. 12-142 (U.S., 6/24/13). Readers will rec

  9. Health Care and Life Sciences

    Title III Healthcare News: Access Board Announces First Meeting of Working Group on Accessible Drug Labels

    By Seyfarth Shaw LLP

    By Kristina M. Launey As noted during our Healthcare webinar last week, the accessibility of drug labels accessible is on the Administration’s agenda.  Yesterday the Access Board announced that the stakeholder…

  10. Drug & Device Law

    Interesting Mensing Application

    By Bexis

    We saw the 360 blurb this morning on In re Darvocet, Darvon & Propoxyphene Products Liability Litigation, MDL Docket No. 2226, slip op. (E.D. Ky. Oct. 10, 2012), and we…